A novel cell based cancer treatment developed, Medical College of Wisconsin

▴ A novel cell based cancer treatment developed, Medical College of Wisconsin
Novel CAR-T Cell immunotherapy for lymphoma advances to phase II clinical trial

A novel cancer therapy studied and developed at the Medical College of Wisconsin (MCW) with promising clinical outcomes is leading to a larger phase II trial to improve on the current standard of care. Results of phase I of the first-in-the-world double targeted chimeric antigen receptor (CAR) T-cell therapy clinical trial were published in Nature Medicine.

This is a novel, cell-based treatment against cancer-targeting two proteins (antigens CD19 and CD20) on the surface of cancer cells. This CAR-T cell therapy trial began in October 2017 and resulted in safe and promising outcomes for patients with relapsed and refractory B cell non-Hodgkin lymphomas which are cancers of the immune system. MCW researchers collected patients' own immune cells (T-cells) and then used a specially engineered virus to augment their ability to identify and kill cancerous cells and effectively destroy the lymphoma. While phase I focused on safety and feasibility of the treatment, a multi-institutional phase II is being developed to determine the true efficacy and understand how the nuances of the treatment process can result in excellent outcomes for a larger subset of patients.

All patients in the clinical trial had failed prior treatments and their cancer had relapsed. Within 28 days of the CAR-T cell therapy, 82 per cent responded positively. Six months later, more than half of the patients' cancer remained in remission. A higher dose of the treatment correlated with a prolonged remission, a trend the researchers plan to study further in the trial's second phase.

"Immuno-oncology using T-cell treatments shows incredible promise for cancer patients," said Nirav Shah, MD, MSHP, principal investigator of the trial, associate professor of medicine in the division of Hematology and Oncology at MCW, and lymphoma and stem cell transplant specialist at the Froedtert & the Medical College of Wisconsin Clinical Cancer Center at Froedert Hospital. "This is a giant leap forward in personalized medicine. Very few cancer centres offer this novel combination of resources and a high level of personalized medicine expertise. The encouraging results of this trial pave the way for more effective and efficient treatment options."

While CAR-T cell therapy has been under development since 2012, the Froedtert & MCW Clinical Cancer Center treated the first patients using this dual-targeted gene therapy. The new treatment genetically alters a person's own immune cells to target cancer cells in a unique and personalized fashion, a significant departure from more routine chemotherapy.

The cell product used for treatment was manufactured using the CliniMACS Prodigy device, which is part of an automated CAR-T cell manufacturing platform developed by Miltenyi Biotec, a global company dedicated to enabling cellular and gene therapies. A collaboration of scientists and clinicians recognized the potential of this treatment several years ago and began acquiring the necessary equipment to prepare for a clinical trial. Housed at the Froedtert & MCW Clinical Cancer Center, the CliniMACS Prodigy device enabled the research team to conduct the CAR-T cell immunotherapy through a self-contained, desktop system, producing new cells ready to be infused back into a patient's bloodstream within 14 days. With the device, the entire process was performed locally at Froedtert Hospital, saving precious time for the patients.

The launch of this clinical trial is the result of decades of collaborative cancer and cellular immunotherapy research at the Blood and Marrow Transplant and Cellular Therapy program. Pioneers in the field of immunotherapy, these researchers worked on ideas of harnessing the body's own immune system to fight cancer cells, leading to innovative alternatives to traditional chemotherapy, radiation and transplants, that are often effective in killing cancer cells but also frequently damage the body's healthy cells. This knowledge paved the way for the CAR-T cell treatment, which trains the patient's own immune cells to kill cancer, rather than relying on foreign, toxic substances.

"We are harnessing knowledge from decades of research to improve outcomes for patients with lymphoma," said Parameswaran Hari, MD, MRCP, MS, senior author and professor and chief of the Division of Hematology and Oncology at MCW, specializing in treating individuals with myeloma, leukaemia and lymphoma at the Froedtert & MCW Clinical Cancer Center. "There is amazing potential here for the future of not just lymphoma patients but patients with many other cancers."

This research was made possible through philanthropic dollars raised by the Children's Wisconsin Foundation and the MACC Fund (Midwest Athletes Against Childhood Cancer, Inc.) and their support of the Cell Therapy Lab at MCW.

"This clinical trial demonstrates the strength of the partnerships across this campus and the power of academic medicine," said David Margolis, MD, program director of the Bone Marrow Transplant (BMT) and Cellular Therapy Program and professor of paediatrics and interim chair of the Department of Pediatrics at MCW. "The expertise of MCW researchers, state-of-the-art facilities of Children's and Froedtert and generosity of this community made this work possible."

Tags : #MedicalCollegeofWisconsin #NatureMedicine #LatestCancerTreatment #LatestPharmaNews0610 #MiltenyiBiotec #BoneMarrowTransplant

About the Author

Team Medicircle

Related Stories

Loading Please wait...


Trending Now

Eyes on the Future: Dr. Agarwal's Group Channels Rs 100 Crore for Cutting-edge Eye Hospitals Across KeralaDecember 06, 2023
Organ Transplant Scandal: Apollo Hospital Faces Government InquiryDecember 06, 2023
Breaking Barriers in Cancer Treatment: Max Healthcare's CAR-T Therapy PartnershipDecember 06, 2023
Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023